ViaCyte, Inc.

141 articles about ViaCyte, Inc.

• 

  Where Are They Now? Top 3 Biotech Startups From NextGen Bio 2016

  2/6/2019

  Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.

• ViaCyte Announces New Board Members

  1/29/2019

  ViaCyte, Inc., a privately-held regenerative medicine company, today announced that following the recent $80 million Series D financing, the Company's Board of Directors has been restructured.

• Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

  1/21/2019

  In preclinical models, implants of PEC-Direct (also known as VC-02) are capable of forming a functional beta cell mass that controls blood glucose levels

• ViaCyte Provides Update on Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

  1/4/2019

  President and CEO Paul Laikind, Ph.D. to give a company update at Biotech Showcase

• ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

  11/29/2018

  Three financing initiatives announced over last three months secure combined commitments of over $100M to drive forward the Company's human cell therapy platform including its clinical-stage islet cell replacement product candidates

• 

  ViaCyte Snags $80 Million to Advance Its Stem-Cell Derived Diabetes Therapies

  11/29/2018

  Two months after striking a deal with CRISPR Therapeutics to tackle diabetes, San Diego-based ViaCyte, Inc. secured $80 million in a Series D financing round to advance the company’s novel stem cell-derived islet replacement therapies for diabetes patients.

• ViaCyte to Present at Investor, Partnering, and Scientific Conferences in October 2018

  9/27/2018

  ViaCyte, Inc. today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and the BIO Investor Forum.

• Gore Strengthens Collaborative Relationship with ViaCyte by Investing Additional $10 Million

  9/25/2018

  ViaCyte and Gore continue to make progress on cell therapy encapsulation technology improvements

• 

  CRISPR Therapeutics and ViaCyte Collaborate to Tackle Type 1 Diabetes

  9/17/2018

  CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.

• ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells

  4/17/2018

  ViaCyte, Inc., a privately held regenerative medicine company, today announced that it has been awarded a Small Business Innovative Research (SBIR) Phase II Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support the further development of functional human beta cells in vitro.

• ViaCyte Announces First Patients Implanted in Cohort 2 with Potentially Efficacious Dose of PEC-Direct Islet Cell Replacement Therapy

  1/5/2018

  This novel cell replacement therapy is being developed as a potential functional cure for patients with type 1 diabetes who are at high risk for acute life-threatening complications.

• CIRM Grants ViaCyte $1.4M to Create Immune-Evasive Pluripotent Stem Cell Lines

  12/15/2017

  ViaCyte today announced that the CIRM approved a grant of $1.4M to support the initial development of immune-evasive pluripotent stem cell lines.

• ViaCyte Awarded New CIRM Grant To Support Clinical Trial Of PEC-Direct Product Candidate For High-Risk Type 1 Diabetes

  9/29/2017

• ViaCyte Announces First Patients Implanted With PEC-Direct Islet Cell Replacement Therapy In International Clinical Trial

  8/1/2017

• ViaCyte Receives IND Allowance From FDA And Clearance From Health Canada To Commence International Clinical Trial Of PEC-Direct Cell Therapy For High-Risk Type 1 Diabetes

  5/22/2017

• ViaCyte Announces $10 Million In Financing

  5/22/2017

• JDRF And ViaCyte Announce Support For Development Of PEC-Direct Cell Replacement Therapy For Type 1 Diabetes

  5/22/2017

• ViaCyte And W. L. Gore & Associates Announce Collaborative Research Agreement To Develop Novel Implantable Delivery Technologies For Cell Therapies

  3/29/2017

• Beyond Type 1 Provides Grant To ViaCyte To Support Research And Development Of Cell Replacement Therapies For Type 1 Diabetes

  2/23/2017

• Twenty-two New Patents Are Added To ViaCyte's Intellectual Property Portfolio

  1/4/2017